Rhumbline Advisers Amylyx Pharmaceuticals, Inc. Transaction History
Rhumbline Advisers
- $105 Billion
- Q2 2024
A detailed history of Rhumbline Advisers transactions in Amylyx Pharmaceuticals, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 28,779 shares of AMLX stock, worth $142,743. This represents 0.0% of its overall portfolio holdings.
Number of Shares
28,779
Previous 69,403
58.53%
Holding current value
$142,743
Previous $197,000
72.59%
% of portfolio
0.0%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding AMLX
# of Institutions
139Shares Held
46.5MCall Options Held
226KPut Options Held
909K-
Vanguard Group Inc Valley Forge, PA4.22MShares$21 Million0.0% of portfolio
-
Aqr Capital Management LLC Greenwich, CT3.34MShares$16.6 Million0.01% of portfolio
-
Black Rock Inc. New York, NY2.67MShares$13.2 Million0.0% of portfolio
-
Goldman Sachs Group Inc New York, NY2.61MShares$12.9 Million0.0% of portfolio
-
Abrdn PLC1.97MShares$9.78 Million0.01% of portfolio
About Amylyx Pharmaceuticals, Inc.
- Ticker AMLX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 58,533,200
- Market Cap $290M
- Description
- Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment...